Skip to main content
. 2018 Jan 17;9(8):8027–8041. doi: 10.18632/oncotarget.24261

Figure 6. Anti-leukemia efficacy of dual JAK2 and mTOR inhibition in vivo in the ATF7IP-JAK2 fusion PDX.

Figure 6

Mice were injected with PDX 16 (ATF7IP-JAK2) and treated as indicated in Figure 5A. Tumor burden was represented by spleen weight and morphology (A, B), engraftment (C) and signaling (D).